Maternally inherited diabetes and deafness (MIDD) is driven by m.3243A>G mitochondrial mutation with mixed β‑cell failure and insulin resistance. GLP‑1 receptor agonists and SGLT2 inhibitors have biologic plausibility and cardiorenal benefits in MIDD; we propose a pathophysiology‑driven treatment algorithm and practical monitoring guidance.